Amylin Pharmaceuticals Inc is categorized under in San Diego, CA and active since 2012.
Amylin Pharmaceuticals Inc was established in 2012, and today employs 1 to 4, earning $500.000.000 to $999.999.999 per year. This is a business, which does work in the BOTH market, and is classified as a , under code number 5417112 by the NAICS.
If you are seeking more information, feel free to contact Mark Gergen, Senior Vice President at the company’s single location by writing to 9625 Towne Center Drive, San Diego, California CA 92121 or by phoning (858) 552-2200. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Amylin Pharmaceuticals Inc |
| Contact Person: | Mark Gergen, Senior Vice President |
| Address: | 9625 Towne Center Drive, San Diego, California 92121 |
| Phone Number: | (858) 552-2200 |
| Website Address: | careers.amylin.com |
| Annual Revenue (USD): | $500.000.000 to $999.999.999 |
| Founded: | 2012 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B & B2C |
| Business Category: | |
| SIC Code: | 2834 |
| NAICS Code: | 5417112 |
| Share This Business: |
Amylin Pharmaceuticals Inc was started in 2012 to provide professional under the SIC code 2834 and NAICS code 5417112. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000.000 to $999.999.999 per annum.
Feel free to contact Mark Gergen, Senior Vice President for inquiries that concern Amylin Pharmaceuticals Inc by calling the company number (858) 552-2200, as your correspondence is most welcome. Additionally, the physical location of the single location of Amylin Pharmaceuticals Inc can be found at the coordinates 32.8819,-117.20869 as well as the street address 9625 Towne Center Drive in San Diego, California 92121.
For its online presence, you may visit Amylin Pharmaceuticals Inc’s website at careers.amylin.com and engage with its social media outlets through on Twitter and on Facebook.